Document Detail


Luteinizing hormone-releasing hormone induces JunD-DNA binding and extends cell cycle in human ovarian cancer cells.
MedLine Citation:
PMID:  12054733     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Expression of luteinizing hormone-releasing hormone (LHRH) and its receptor as part of an autocrine regulatory system of cell proliferation has been demonstrated in a number of human malignant tumors, including cancers of the ovary. This study was conducted to investigate whether LHRH induces activation of JunD and affects cell cycle regulation and DNA synthesis. Treatment of primary human ovarian cancer cells and human ovarian cancer cell lines EFO-21 and EFO-27 with LHRH agonist triptorelin (100 nM) resulted in an increase in G(0/1) phase and a decrease in G(2/S) phase of cell cycle. Treatment of quiescent EFO-21 or EFO-27 cells with triptorelin (100 nM) resulted in a 46.7 or 44.2-fold increase of AP-1 activation, respectively (p<0.001). Maximal binding of JunD on DNA consensus sequence was found after 4 h of treatment of quiescent EFO-21 or EFO-27 cells with triptorelin (100 nM). DNA synthesis was significantly decreased to 45.5+/-11.4% (day 0=control=100%; p<0.001) after 3 days of triptorelin (1 nM) treatment. These results suggest that LHRH agonist triptorelin induces JunD-DNA binding, resulting in reduced proliferation as indicated by increased G(0/1) phase of cell cycle and decreased DNA synthesis. Since LHRH activates nucleus factor kappa B (NF kappa B) and protects ovarian cancer cells from doxorubicin-induced apoptosis and JunD is shown to decrease cell cycle and cell proliferation, we propose that JunD activated by LHRH acts as a modulator of cell proliferation and cooperates with the anti-apoptotic and anti-mitogenic functions of LHRH.
Authors:
Andreas R Günthert; Carsten Gründker; Kirsten Hollmann; Günter Emons
Related Documents :
17585503 - Asymmetric distribution of dna between daughter cells with final symmetry breaking duri...
21911443 - New insights into the role of centrosomes in mammalian fertilisation and implications f...
15036853 - Role of 2'-2' difluorodeoxycytidine (gemcitabine)-induced cell cycle dysregulation in r...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Biochemical and biophysical research communications     Volume:  294     ISSN:  0006-291X     ISO Abbreviation:  Biochem. Biophys. Res. Commun.     Publication Date:  2002 May 
Date Detail:
Created Date:  2002-06-10     Completed Date:  2002-07-22     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  0372516     Medline TA:  Biochem Biophys Res Commun     Country:  United States    
Other Details:
Languages:  eng     Pagination:  11-5     Citation Subset:  IM    
Affiliation:
Department of Gynecology and Obstetrics, Georg-August-University, Robert-Koch-Street 40, D-37075 Göttingen, Germany.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adenocarcinoma / genetics,  pathology
Aged
Antineoplastic Agents, Hormonal / pharmacology
Apoptosis / drug effects
Cell Cycle / drug effects*
DNA / metabolism*
DNA Replication / drug effects
DNA, Neoplasm / biosynthesis
Female
Flow Cytometry
Gonadotropin-Releasing Hormone / pharmacology*
Humans
Ovarian Neoplasms / genetics,  pathology*
Proto-Oncogene Proteins c-jun / metabolism*
Triptorelin / pharmacology
Tumor Cells, Cultured
Chemical
Reg. No./Substance:
0/Antineoplastic Agents, Hormonal; 0/DNA, Neoplasm; 0/Proto-Oncogene Proteins c-jun; 33515-09-2/Gonadotropin-Releasing Hormone; 57773-63-4/Triptorelin; 9007-49-2/DNA

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Synthesis, aggregation, neurotoxicity, and secondary structure of various A beta 1-42 mutants of fam...
Next Document:  NS3 protease of Langat tick-borne flavivirus cleaves serine protease substrates.